Inovio Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Inovio Pharmaceuticals Inc.
SPDR S&P Biotech ETF
2,623,020
2.87%
6,747
0.24%
09/06/2018
Vanguard Total Stock Market Index Fund
2,214,985
2.42%
57,093
0%
07/31/2018
iShares Russell 2000 ETF
1,762,107
1.93%
-942
0.02%
09/06/2018
ARK Genomic Revolution Multi Sector ETF
1,646,532
1.8%
9,193
2.81%
09/05/2018
Wasatch Small Cap Growth Fund
1,218,886
1.33%
0
0.31%
03/31/2018
Vanguard Extended Market Index Fund
1,127,159
1.23%
0
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,042,968
1.13%
-13,629
0.06%
09/06/2018
iShares Russell 2000 Growth ETF
806,116
0.88%
0
0.04%
09/06/2018
Fidelity Spartan Extended Market Index Fund
369,930
0.4%
0
0.01%
07/31/2018
Guggenheim Mid Cap Value Fund
285,661
0.31%
0
0.31%
07/31/2018
| Address |
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462
United States
|
|
Employees
|
- |
| Website |
http://www.inovio.com |
| Updated |
07/08/2019 |
| Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA. |
